公司資料
Zura Bio 股價、新聞與催化劑
- 股票代碼:
- ZURA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
5.68 USD (+1.97%)
收盤價
最後更新: 2026年8月17日
389M USD
市值
股價為何變動
As of Aug 17, 2026, ZURA closed up 1.97% at $5.68. No new same-company headline was identified in the current news window.
公司概覽
Autoimmune and Inflammatory Diseases
Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules.
Tibulizumab
Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell biology involved in chronic immune-mediated disease.
TibuSHIELD
The Phase 2 TibuSHIELD study evaluates tibulizumab in adults with hidradenitis suppurativa, an inflammatory skin disease driven in part by IL-17 signaling.
TibuSURE
The Phase 2 TibuSURE study evaluates tibulizumab in adults with systemic sclerosis, where simultaneous IL-17 and BAFF inhibition may address inflammation, autoantibodies, and fibrosis.
NEXUS-PMR
Zura selected polymyalgia rheumatica as a third indication for tibulizumab. The planned Phase 2 NEXUS-PMR study extends the program into an inflammatory disorder commonly treated with long-term glucocorticoids.
未來催化劑
- Topline data from the Phase 2 TibuSHIELD study in the fourth quarter of 2026.
- Initiation of the Phase 2 NEXUS-PMR study by the end of 2026.
- Topline data from the Phase 2 TibuSURE study in the first half of 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。